Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/25/2025

Type 2 Diabetes Management Guidelines

Introduction to Updated Guidelines

  • The American Diabetes Association recommends prioritizing organ protection over glycemic control alone, selecting medications based on the presence of heart failure, chronic kidney disease, or cardiovascular risk rather than HbA1c alone 1, 2

First-Line Therapy

  • Metformin plus lifestyle modifications remain mandatory first-line therapy for all adults with type 2 diabetes unless contraindicated 1, 2
  • Monitor vitamin B12 levels during long-term metformin use, particularly if anemia or peripheral neuropathy develops 1, 2

Second-Line Therapy

  • When metformin fails to achieve HbA1c targets, add SGLT2 inhibitor if patient has heart failure, or CKD, or cardiovascular risk 1, 2, 3, 4, 5
  • Add GLP-1 receptor agonist if patient has increased stroke risk or needs substantial weight loss 1, 3, 4, 5

Glycemic Targets

  • The American College of Physicians recommends HbA1c between 7-8% for most adults, moving away from the traditional <7% target 3, 4, 5
  • Deintensify treatment when HbA1c falls below 6.5% to avoid hypoglycemia and overtreatment 3, 4, 5

Medication Selection

  • GLP-1 receptor agonists are preferred over insulin, with a Grade A recommendation 1, 2
  • Combination therapy with a GLP-1 agonist is recommended if insulin is ultimately required 1

Discontinuation of Inferior Medications

  • Discontinue sulfonylureas and long-acting insulins when SGLT2 inhibitors or GLP-1 agonists achieve adequate glycemic control, due to increased severe hypoglycemia risk 3, 4, 5

Weight Management

  • Weight management is now explicitly integrated into diabetes treatment algorithms, with glucose-lowering treatment plans supporting weight management goals 1, 2

Monitoring and Reassessment

  • Medication plans must be reevaluated every 3-6 months and adjusted based on glycemic control, weight goals, metabolic comorbidities, and hypoglycemia risk 1, 2

Cost Considerations

  • Discuss medication costs with patients when selecting from SGLT2 inhibitors or GLP-1 agonists, and prescribe generics when available 3, 4, 5

Social Determinants of Health

  • Health systems must assess social risk factors and connect patients with adverse social determinants to community services 3, 4, 5